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While leukemia-originating stem cells are critical in the ini-
tiation and maintenance of leukemias, the existence of sim-
ilar cell populations that may generate B-cell lymphoma
upon mutation remains uncertain. Here we propose that
committed lymphoid progenitor/precursor cells with an
active V-D-J recombination program are the initiating cells
of follicular lymphoma and mantle cell lymphoma when
targeted by immunoglobulin (IG)- gene translocations in
the bone marrow. However, these pre-malignant lym-
phoma-initiating cells cannot drive complete malignant
transformation, requiring additional cooperating mutations
in specific stem-cell programs to be converted into the lym-
phoma-originating cells able to generate and sustain lym-
phoma development. Conversely, diffuse large B-cell lym-
phoma and sporadic Burkitt’s lymphoma derive from B
lymphocytes that acquire translocations through IG-hyper-
mutation or class-switching errors within the germinal cen-
ter. Although secondary reprogramming mutations are
generally required, some cells such as centroblasts or mem-
ory B cells that have certain stem cell-like features, or lym-
phocytes with MYC rearrangements that deregulate self-
renewal pathways, may bypass this need and directly func-
tion as the lymphoma-originating cells. An alternative
model supports an aberrant epigenetic modification of
gene sets as the first occurring hit, which either leads to
retaining stem-cell features in hematopoietic stem or pro-
genitor cells, or reprograms stemness into more committed
lymphocytes, followed by secondary chromosomal
translocations that eventually drive lymphoma develop-
ment. Isolation and characterization of the cells that are at
the origin of the different B-cell non-Hodgkin’s lymphomas
will provide critical insights into the disease pathogenesis
and will represent a step towards the development of more
effective therapies. 
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Introduction
Stem cells are primarily characterized by the properties of
unlimited self-renewal, which maintains and expands the
undifferentiated cell pool over the lifetime of the host, and
multi-lineage differentiation, which produces progeny of diverse
mature phenotypes to generate and regenerate tissues.1 These
stem cell attributes are tightly regulated in normal develop-
ment, yet their alteration may lead to many human diseases
including cancer. In fact, because stem cells and some cancer
cells share self-renewal and differentiation capacities, it was
suggested that tumors were derived from mutated stem cells,
the so-called cancer stem cells.1-3 Although this hypothesis was
postulated in early reports,4-6 definite proof of their existence
came from recent studies in leukemia, where among the com-
plete tumor cell population only a small subset of cells could
initiate, regenerate and maintain the leukemia after transplan-
tation into immunocompromised mice.7,8 Using similar func-
tional approaches, a variety of cancer stem cells have been
identified in an increasing number of epithelial tumors, includ-
ing breast, prostate, pancreatic, and head and neck carcino-
mas, all of which were distinguished by the expression of the
cell-surface glycoprotein CD44.9Another cell surface marker,
the CD133 glycoprotein, defined the tumor-initiating cells of
brain and colon carcinomas.9-11 The concept of cancer stem
cells is not only changing our current understanding of cancer
biology, but may also have profound consequences on cancer
diagnostics and therapeutics. For example, gene expression
profiles associated with the stemness/differentiation states of
tumors might be used as molecular predictors of therapeutic
outcome.12,13 In addition, studies in glioblastoma and breast
cancers support the view that cancer stem cells are more
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resistant to radiotherapy and chemotherapy-induced apop-
tosis, which allows these cells to survive and generate
tumor relapse.14,15 A prototypical example of a stem cell dis-
order is chronic myeloid leukemia (CML), where the tyro-
sine kinase inhibitor imatinib has replaced IFNa as the
standard therapy.16 However, clinical trials have not shown
the expected cure rates with the use of imatinib, as a con-
sequence of this compound being active against differenti-
ated CML progenitors while presenting limited activity
against quiescent CML stem cells.17 Consequently, many
patients in apparent complete molecular remission
relapsed when the drug was discontinued.17,18 These data
suggest that CML stem cells would constitute a reservoir
responsible for disease relapse, a phenomenon which may
also occur in other cancers. 
Despite these outstanding discoveries in leukemias and
solid tumors, the existence of lymphoma-originating cells
with stem-cell properties that may similarly generate lym-
phoma upon mutation remains a controversial and largely
unexplored issue.19
Indeed, a recent study identified rare clonal B lympho-
cytes expressing CD20, the memory B-cell antigen CD27,
and the stem cell marker aldehyde dehydrogenase (ALDH)
that may be responsible for the generation and mainte-
nance of the predominant Hodgkin and Reed-Sternberg
cells in classical Hodgkin’s lymphoma.20 These data point
to these B lymphocytes as the originating cells for
Hodgkin’s lymphoma, and opens a debate on whether this
is also the case for the different B-cell non-Hodgkin’s lym-
phomas.20,21 Consequently, here we review the role of the
diverse hematopoietic and lymphoid cell populations as
the putative cells of origin for the B-cell lymphoma sub-
groups, highlighting the similarities and differences with
other known stem cell-derived cancer models. 
Chromosomal translocations as the first occurring genet-
ic hit in B-cell lymphomas
The different acute myeloid leukemia (AML) subgroups
were shown to be derived from a common leukemia stem
cell (LSC) that shares a CD34+CD38– phenotype with nor-
mal hematopoietic stem cells (HSCs).8,22 The similarities
between HSCs and LSCs strongly suggest that HSCs can be
the source of LSCs when targeted by oncogenic transloca-
tions. Instead, more committed progenitors may also be
transformed into LSCs through the accumulation of appro-
priate mutations that restore the critical stem-cell abilities
of self-renewal and multi-differentiation (Figure 1). But are
lymphomas, a group of disorders also characterized by
oncogenic chromosomal translocations, derived from
hematopoietic stem cells or from committed lymphoid
progenitors? The study of normal lymphocyte lineage
development together with the analysis of the molecular
structure of the chromosomal translocations involving
immunoglobulin (IG) genes can help to assign the putative
lymphoma-initiating cells to specific developmental stages
(Figure 2).23-28 Errors in any of the physiological IG gene
rearrangements may result in aberrant chromosomal
translocations involving IGH (or more rarely IGL or IGK)
genes, which usually become juxtaposed to a variety of
oncogenes, and are characteristic of the different lym-
phoma subtypes.27 Direct proof of the involvement of the
V-D-J recombination process in the generation of lym-
phoma translocations has been provided, as the DNA of the
BCL2 major translocation breakpoint acquires an altered
structure that is cut by RAG nucleases, which regulate V-D-
J recombination.29 Molecular analysis of translocation
breakpoints provides insights into their timing of occur-
rence during B-cell differentiation. In the t(14;18)(q32;q21)
involving BCL2 in follicular lymphoma (FL), in the
t(11;14)(q13;q32) targeting CCND1 in mantle cell lym-
phoma (MCL), and in the t(14;18)(q32;q21) deregulating
MALT1 gene in mucosa-associated lymphoid tissue
(MALT), the gene rearrangements usually involve the non-
functional IG gene at the 5’ end of J heavy-chain (JH) gene
segments, pointing to mistakes occurring at the DH to JH
stage in bone marrow lymphoid progenitors (ELPs and
CLPs) or in B-cell precursors (pro-B and pre-B cells).23,27,30
However, one-third of BCL2-IGH gene rearrangements in
FL occur at later V-D-J recombination stages (primarily VH
to DHJH), involving pre-B or immature B cells.31,32 In any case,
FL cells invariably show somatic hypermutation (SHM) of
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Figure 1. Leukemia-originating stem cell model. Functional studies
in acute myeloid and chronic leukemias have led to the identifica-
tion and characterization of the leukemia-originating stem cells
(LSCs), which share features with normal hematopoietic stem cells
(HSCs). LSCs derive either from HSCs, multipotent progenitors
(MPPs), committed progenitor cells or even more differentiated
cells that accumulate mutations that reprogram the necessary
stem-cell features to generate and regenerate tumors. 
both IGH alleles, suggesting that the immortalized B cells
with BCL2 overexpression must have continued their nor-
mal differentiation path including the transit through the
germinal center. In contrast, most MCL cases show unmu-
tated IGH genes, reflecting that B cells with acquired
CCND1 translocations did not enter the germinal center. 
A set of molecularly different chromosomal transloca-
tions are promoted by the process of SHM.26 In normal ger-
minal-center lymphocytes, this mechanism generates point
mutations, deletions and duplications in the variable
regions of the IG genes that are intimately associated with
DNA cleavage and can be recombinogenic.33 Aberrant
hypermutation activity can also target BCL6 and other
oncogenes such as PIM1, MYC, RhoH and PAX5 in germi-
nal center-derived lymphomas and in Hodgkin’s lym-
phoma.34-36 Mutations are distributed in the 5' untranslated
or coding sequences, regions that are commonly disrupted
by chromosomal translocations, consistent with a role for
SHM in generating these translocations by DNA double-
strand breaks. Accordingly, BCL6 fuses its 5´ untranslated
sequences with either IG genes or with a large variety of
partner genes in DLBCL.37 A third class of chromosomal
translocations occurs in IG switch sequences through an
illegitimate class-switch recombination (CSR) process in
the germinal center. As an example, in most sporadic
Burkitt’s lymphomas with t(8;14)(q24;q32), the MYC
oncogene fuses to IGH µ switch (Sµ) region, whereas
endemic Burkitt’s lymphomas display breakpoints in the JH
region.38,39 Similar rearrangements targeting IGH Sµ
sequences are observed in DLBCL with t(3;14)(q27;q32)
involving the 5´ unstranslated region of BCL6, and in mul-
tiple myeloma with translocations of IRF4, c-MAF, FGFR3
and MMSET oncogenes.26,27,37,40 Most tumors with CSR-
related translocations show concomitant hypermutation of
IG genes, consistent with cell germinal center transit.
However, a few cases of low grade B-cell lymphoma with
CSR-related translocations, including the t(14;19)(q32;q13)
involving BCL3 gene or the t(2;14)(p13;q32) targeting
BCL11A, displayed non-mutated IGH gene sequences.41,42
An explanation for these cases is that the translocation
occurred in activated B cells in the course of T-cell inde-
pendent immune responses outside the germinal center.
Lastly, rare cases of FL display CSR-related BCL2-IGH
rearrangements, indicating a late germinal center origin.43
Importantly, in FL and in some germinal center-derived
DLBCL cells, the presence of intraclonal IGH nucleotide
variation indicates that the translocation t(14;18)(q32;q21)
must have occurred in pre-germinal or early germinal cen-
ter B lymphocytes (possibly centroblasts in the dark zone
of the germinal center), after which divergences in the
SHM and CSR processes gave rise to different clones with
heterogeneous IG sequences and multiple isotype tran-
scripts.44,45 Moreover, these lymphomas usually present
variation in the pattern of IG hypermutation during disease
progression.46 Conversely, ongoing SHM of IG genes is
rarely observed in DLBCL with activated B-cell phenotype,
but instead, aberrant CSR and IGH switch translocations
involving different oncogenes are common.47 These data
indicate that activated B-cell DLBCL may be derived from
B lymphocytes (possibly centrocytes) in transit through the
light zone of the germinal center, where CSR but not SHM
take place normally.44,47
Lymphoma stem cells
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Figure 2. Schematic representation of the normal lymphoid cell
development. HSCs generate multipotent progenitors (MPPs) that
are committed to form either common myeloid progenitors (CMPs)
or early lymphoid progenitors (ELPs). ELPs differentiate into com-
mon lymphoid progenitors (CLPs), which are restricted to lymphoid
development, giving rise to B cells, T cells, dendritic cells and natu-
ral killer cells. Expression of the B-cell marker B220 by a subset of
CLPs (known as pro-B cells) indicates their entry into the B-cell dif-
ferentiation pathway. However, the process of IG gene remodeling is
initiated earlier by ELPs, with the assembly of genes for the variable
regions of the IG heavy (IGH) and light (IGL) chains in a process
called V-D-J gene recombination. This event occurs prior to contact
with antigen, and the molecular anatomy of the productive V-D-J
rearrangements suggests that nuclear terminal deoxynucleotidyl
transferase (Tdt) is involved. Immature B cells then leave the bone
marrow microenvironment and populate the peripheral lymphoid
organs. It is here that these naïve B cells contact antigen and lead
to the formation of the germinal centers of secondary lymphoid
organs, where some of them continue BCR modification to increase
affinity for the immunizing antigen. This secondary phase of BCR
remodeling requires two different mechanisms unique to the germi-
nal center, IG class-switch recombination (CSR) and somatic hyper-
mutation (SHM). During CSR, B cells change the isotype of the
expressed BCR, while SHM introduces nucleotide changes, deletions
and duplications at a very high frequency in both productive and
non-productive IG genes, resulting in the generation of antibody
variants. These mechanisms require the activation-induced cytidine
deaminase (AICDA). Finally, cells expressing favorable antibody
mutants are positively selected, vigorously expanded and released
into the periphery as IG-secreting plasma cells or long-lived memo-
ry B cells. B-cell ontogeny-determining transcription factors are
shown, indicating whether they are activated (+) or inhibited (–) dur-
ing each cellular step. 
Evidence to support that B-cell lymphomas originate
from common lymphoid progenitor or precursor cells
Initial support for the existence of clonogenic cells that
may be the origin of lymphoma was gleaned from the
molecular analysis of composite lymphomas.48 The study
of patients presenting with both Hodgkin’s and non-
Hodgkin’s lymphoma demonstrated the same clonal IGH
gene rearrangements in the Reed-Sternberg cells and in
non-Hodgkin’s lymphoma cells; however, the IGH somat-
ic hypermutation pattern in each lymphoma was differ-
ent.49,50 These data suggested that lymphomas were
derived from a common B-cell precursor cell that acquired
the BCL2 gene rearrangement and then diverged to gener-
ate clonally distinct tumors (Figure 3A). One patient simul-
taneously developed MCL and Hodgkin’s lymphoma, both
with identical CCND1 translocation. However, MCL cells
showed unmutated IGH genotype whereas SHM was
observed in Hodgkin’s lymphoma cells.50 These data fur-
ther support the occurrence of the CCND1 translocations
in MCL in pre-germinal center B cells (Figure 3B). 
Conversely, germinal-center B cells may also be the initi-
ating cells of some composite lymphomas. A patient devel-
oped DLBCL and Hodgkin’s lymphoma, both with identi-
cally hypermutated IGH genes. However, a P53 gene bi-
allelic mutation was detected only in DLBCL cells (Figure
3C). These data suggest that a late germinal center B-cell
initiated both lymphomas, and that subsequent P53 inacti-
vation led a fraction of cells towards development of
DLBCL.50 The transmission of an FL by bone marrow
transplantation (BMT) further supports the existence of a
germinal center lymphoma-originating cell.51 In 1992, a 32-
year old man developed AML, for which he received allo-
geneic BMT from his father, after which he remained in
remission. Three years later the patient’s father was diag-
nosed with FL. Although he received therapy, he died of
the disease. In 2003, eleven years after the diagnosis of
AML, the son developed FL, and despite a good initial clin-
ical response, his disease slowly progressed.52 Both lym-
phoma biopsies in father and son revealed identical BCL2-
IGH gene rearrangements. In addition, both tumors had
identical DH-JH allele-types and shared SHM patterns that
defined a putative common precursor cell with 91%
homology to the VH germline sequence of IGH. Although
the first genetic hit (the BCL2-IGH chromosomal translo-
cation) must have occurred in a precursor B lymphocyte
(the lymphoma-initiating cell), the genetic similarity
between the father’s and the son’s lymphomas points to a
germinal-center B lymphocyte as the lymphoma-originat-
ing cell for both subjects’ tumors (Figure 3D).
Further compelling evidence arguing in favor of the exis-
tence of a common lymphoma-initiating cell in FL comes
from cytogenetic and genotyping studies of sequential
biopsies of patients undergoing histological transformation
from FL to DLBCL (t-DLBCL). Classical karyotyping and
comparative genomic hybridization studies of paired spec-
imens revealed that the transformed biopsy shares some,
but not all, of the alterations evident in the diagnostic FL
sample.53,54 This finding suggests subclone selection or
divergent outgrowth of a common malignant ancestral cell
in contrast to clonal evolution resulting from stochastic
genetic events, only some of which provide a selective
advantage. Moreover, recent studies have reported that
transformation of FL to t-DLBCL occurs over approximate-
ly 15-17 years following a diagnosis of FL and seems to
have a constant rate of 3% per year.55,56 These results sug-
gest that a sizable proportion of the patients with FL may
not be at risk to transform. If clonal selection and evolution
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Figure 3. B-cell progenitors or germinal-center B lymphocytes as the
lymphoma-initiating originating cells in composite lymphomas. (A)
Composite lymphoma with Hodgkin’s and follicular lymphoma, both
carrying identical BCL2-IGH chromosomal translocation and differ-
ent IG somatic hypermutation patterns, indicating that the translo-
cation occurred in a cell before entering the germinal center. (B)
Composite lymphoma with mantle cell lymphoma (MCL) and
Hodgkin’s lymphoma, both with identical CCND1-IGH chromosomal
translocation. However, MCL did not show somatic hypermutation of
IG genes, pointing to a pre-germinal center cell as the initiating cell
for both lymphomas. (C) In a Hodgkin’s and non-Hodgkin’s (diffuse
large B-cell lymphoma, DLBCL) composite lymphoma, both tumors
shared a common IG somatic hypermutation pattern, but differed on
the P53 gene mutation status, which was only observed in the
DLBCL cells. This finding suggests a germinal-center B lymphocyte
as the cell suffering the first genetic event. (D) Transmission of fol-
licular lymphoma by bone marrow transplantation. Both the donor
and recipient presented identical BCL2-IGH rearrangement and IG
hypermutation pattern, suggesting that the cell that transmitted the
lymphoma, the lymphoma-originating cell, was a germinal center B
lymphocyte, although the chromosomal translocation resulting in
the BCL2-IGH fusion occurred in a pre-germinal center lymphocyte. 
were the primary drivers of this process, one might expect
the rate of histological transformation to change over time.
The observed steady-state risk of transformation might be
better modeled if a precursor cell pool with limited prolif-
erative capacity existed and was at-risk for stochastic
genetic events, some of which provide a growth advan-
tage. 
Plasticity of lymphoid cells: generation of the
lymphoma-originating cells through the second hit 
Most of the oncogenes targeted by translocations in B-
cell lymphomas are regulators of lymphocyte proliferation,
apoptosis, development and differentiation pathways, but
do not have a defined role in stem-cell self-renewal pro-
grams.27 If we accept that the translocations in FL and MCL
target either B-cell progenitors or precursors within the
bone marrow that do not conserve stem-cell properties,
these pre-malignant lymphoma-initiating cells need to
restore the necessary stemness to generate and maintain
the tumor, thus becoming the lymphoma-originating cells.
This cellular reprogramming must be achieved through
mutations in genes controling stemness and/or pluripoten-
cy pathways. In germinal center-derived lymphomas, the
initiating translocations seem to target more mature lym-
phocytes within the germinal center, and in most cases
these cells also need to accumulate secondary reprogram-
ming mutations. However, there may be exceptions to this
rule, such as (i) the translocations occurring in centroblasts
or in centrocytes, which are cells that can have certain
stem-cell properties; (ii) translocations/mutations in mem-
ory B cells, which have self-renewal capacity to maintain
life-long immunological memory; and (iii) the transloca-
tions involving the MYC oncogene, which deregulate self-
renewal pathways in the targeted lymphocytes (see
below).57-60 In these cells, the occurrence of secondary
mutations may not be necessary, as they can directly
become the lymphoma-originating cells able to produce
lymphoma. Currently, there is compelling evidence for the
enormous plasticity of B cells in physiological and patho-
logical conditions, and some of the gene pathways that
regulate these stem cell properties are beginning to be char-
acterized.61-65
PAX5 and CEBPα/β transcription factors
Mouse and human somatic cells can be reprogrammed
into pluripotent stem cells by introducing a combination of
factors (OCT3/4, SOX2, MYC, KLF4, NANOG or LIN28)
under certain cell culture conditions.66-68 This exceptional
plasticity is also observed in lymphocytes, where expres-
sion of CEBPα/β transcription factors was sufficient to
reprogram differentiated B cells into macrophages by
inhibiting PAX5.62 The most convincing demonstration of
the plasticity of mature B cells was provided by Cobaleda
and colleagues by generating conditional PAX5 deletion
mutants in mice that allowed mature B cells from periph-
eral lymphoid organs to dedifferentiate back to early
uncommitted progenitors.65 In addition, these mice lacking
PAX5 in mature B cells developed progenitor cell-derived
B-cell lymphomas.65 More recently, reprogramming of ter-
minally differentiated mouse mature B lymphocytes to a
pluripotent state was achieved by expression of OCT4,
SOX2, KLF4 and MYC plus either ectopic expression of
CEBPα/β or specific knock-down of PAX5.64 These reports
underscore that the reprogramming capacity of lymphoid
cells possibly represents a critical and necessary feature of
lymphomagenesis.64,65 However, genetic or epigenetic
mutations of PAX5 or CEBPα/β genes are not commonly
found in lymphoma biopsies, and thus their implication in
human B-cell lymphomas is not completely clear.
Conversely, in B-cell precursor acute lymphoblastic
leukemia (BCP-ALL), inactivating mutations of PAX5 are
frequent, suggesting that these rearrangements may con-
tribute to the cellular differentiation arrest observed in this
disorder.69 Indeed, five members of the CEBP family of
transcription factors can be over-expressed through IG-
related chromosomal translocations in a subset of BCP-
ALL.70 In these cases, CEBP proteins may have inhibited
PAX5 aberrantly, thereby promoting B-cell arrest.62,71
MYC oncogene
MYC is mutated and deregulated in a large proportion of
B-cell lymphomas of different subgroups through various
genetic mechanisms.27,35,38,39 Unlike other lymphoma onco-
genes, forced expression of MYC in murine lymphoid cells
is sufficient to generate B-cell leukemia and lymphoma.72 In
addition, MYC activation is necessary to develop lym-
phoma in BCL2 or CCND1 transgenic mice.73,74 These
oncogenic features may in part rely on the role of MYC as
a regulator of the balance between self-renewal and differ-
entiation in HSCs.57 Accordingly, MYC is among the few
key players inducing pluripotency in somatic and embry-
onic cells and mature lymphocytes.64,66-68 A recent study
revealed that tumor growth in a mouse model of Eµ-MYC
lymphoma need not be driven by rare cancer stem cells but
rather, and in contrast to most leukemias, a large popula-
tion of tumor cells was able to initiate and sustain lym-
phoma development.75 One possible explanation of these
data might be that the MYC oncogene confers stem-cell
properties to a large number of lymphoma cells within the
tumor. 
The Polycomb protein BMI1
Proteins belonging to the Polycomb group (PcG) are epi-
genetic silencers that regulate lymphopoiesis by forming
multimeric complexes that bind and remodel chromatin,
thus regulating gene activity.76 Some PcG genes have been
implicated in lymphomagenesis.77 Forced expression of the
PcG protein BMI1 in lymphocytes was associated with
lymphoma generation, whereas BMI1 gene is amplified
and over-expressed in human MCL and in other B-cell lym-
phomas.77-79 BMI1 has essential roles in regulating prolifer-
ation and self-renewal of both normal and leukemic stem
cells.80 These findings underscore a potential critical charac-
teristic of mutated BMI1 in lymphomagenesis by repro-
gramming pre-malignant lymphocytes bearing different
chromosomal rearrangements into lymphoma-originating
cells with de novo stem cell-like properties. 
Lessons from mouse models of leukemia and
lymphoma
A number of reports have demonstrated the transforma-
tion potential of known leukemia oncogenes in the differ-
ent mouse hematopoietic cell compartments. Short-lived
myeloid progenitors transduced with MLL-ENL, MOZ-
Lymphoma stem cells
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TIF2 and MLL-AF9 oncogenic fusions generated AML with
similar latencies and characteristics to those observed in
long-term HSC models.81-84 As normal myeloid progenitors
do not conserve stem-cell features, those oncogenic
rearrangements must have restored self-renewal and
pluripotent abilities necessary for leukemic transformation,
as was demonstrated by Krivtsov and colleagues in an
MLL-AF9 transgenic model.83 In BCP-ALL, oncogenic
fusions may similarly awaken stem-cell properties in com-
mitted B lymphocytes. In one report, the common genetic
rearrangements observed in patients with BCP-ALL were
modeled in mice (including p190-BCR-ABL and TEL-AML1
gene fusions), concluding that these leukemias were
derived from committed B-cell progenitor cells rather than
from HSCs.85 However, the analysis of human BCP-ALL
samples did not confirm these findings but revealed that
the blasts representative of all of the different maturational
lymphoid stages were able to reconstitute and re-establish
the complete leukemic phenotype in vivo.86 Further studies
in monochorionic twins with BCP-ALL carrying a TEL-
AML1 rearrangement led to the isolation of a
CD34+CD19+CD38– cell population able to initiate a pre-
leukemic state that eventually transformed to frank BCP-
ALL.87 Analysis of TEL-AML1-transduced human cord
blood cells suggested that this rearrangement may function
as a first-hit mutation that also endows these pre-leukemic
cells with altered self-renewal and survival properties, suf-
ficient for leukemia development.87
In contrast to leukemia, many engineered mice express-
ing specific lymphoma oncogenes have failed to generate
the expected human-like lymphomas in vivo. Mice in
which the human CCND1 oncogene was juxtaposed to
the IGµ-chain gene (Eµ-CCND1), which restricts the
expression of the oncogene in the lymphoid compart-
ment,73 did not develop malignancy spontaneously, requir-
ing the cooperation of additional activating mutations to
drive lymphoma formation.74 The Eµ-MYC transgenic
mice developed lymphoma with histopathological features
of human lymphoblastic lymphoma rather than Burkitt’s
lymphoma, lacking for instance the typical germinal cen-
ter-associated IGH somatic hypermutations.72,88 Similarly,
the Eµ-BCL2 mice developed high-grade B-cell lymphoma
after a significant latency period, but not human-like FL.89
Failure of these models to recapitulate human disease may
rely on the inappropriate selection of the cell compartment
in which the oncogenes were expressed and/or on their
inability to restore self-renewal and pluripotent states in
lymphoid progenitors or in more mature B cells.
Supporting these hypotheses, the vavP-BCL2 transgenic
mice, which present constitutive BCL2 overexpression
from HSCs to mature B cells, developed lymphoma that
was preceded by germinal center hyperplasia, thus mim-
icking human FL.90 Unlike Eµ-BCL2 transgenes, vavP-BCL2
mice showed higher levels of BLC2 in T cells, causing
enlargement of the peripheral T-cell compartment, which
was critical to generate abundant germinal centers where B
cells underwent IG hypermutation and class switching,
eventually leading to FL (Figure 4A). These data in mice are
compatible with the portrait of human FL, where micro-
environmental cells that surround tumor cells, including
several T-cell subsets, appear crucial for lymphoma forma-
tion and maintenance.91 These findings theoretically pro-
vide support for either a hematopoietic stem cell or a lym-
phoid progenitor cell as the putative FL-initiating cells, as
they are able to permit BCL2 expression in both B- and T-
cell lineages. However, hematopoietic stem cells do not
seem to have the functional V-D-J machinery subsidiary to
suffer mechanistic errors leading to chromosomal
breaks.23,24 Conversely, lymphoid progenitor cells may have
started V-D-J recombination and are prone to suffer
translocations, thus representing the ideal FL-initiating
cells. However, these cells have lost self-renewal and multi-
differentiation potentials, therefore needing additional
reprogramming mutations to restore stem-cell features. If
these secondary genetic alterations do not occur, BCL2-
expressing lymphocytes may circulate for several years
without giving rise to FL.92
Engineered mice with full-length murine BCL6 placed
downstream of the IG heavy chain (Iµ) promoter (Iµ-BCL6
mice) led to an increase in germinal center formation fol-
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Figure 4. Cells of origin for B-
cell lymphomas according to
mouse models of disease. (A)
The vavP-BCL2 mice show
BCL2 expression in all
hematopoietic cell popula-
tions, and promoted follicular
lymphoma development that
was preceded by germinal
center hyperplasia, thus mim-
icking human FL development.
(B) In the Iµ-BCL6 mice, BCL6
is expressed in mature B cells.
Development of DLBCL is
dependent on the acquisition
of secondary mutations able
to dedifferentiate back pre-
malignant B cells into lym-
phoma-originating stem cells. 
lowed by the generation of DLBCL between 15 and 20
months of age.93 These tumors were developed through
expression of BCL6 in mature B-lymphocytes, resembling
the cellular and genetic features of human germinal center-
derived DLBCL. Because of the long latency period, the
cells carrying the initiating BCL6 alteration possibly
required late secondary mutations to drive malignant
transformation (Figure 4B). Remarkably, crossing Iµ-BCL6
mice with mice lacking AID, the enzyme required for both
SHM and CSR, prevented development of BCL6-driven
DLBCL, suggesting that AID is required for germinal cen-
ter-derived lymphomas.94 Another interesting model is an
AID-dependent conditional MYC transgene (the Vk*MYC
mice), which allowed MYC activation in germinal center B
lymphocytes.95 Despite theoretically resembling the
dynamics of human Burkitt’s lymphoma, these animals
develop multiple myeloma. MYC activation was caused by
AID-dependent SHM, because crossing Vk*MYC mice
with AID knockout mice failed to activate the SHM/CSR
machinery and thus to generate myeloma.95 Indeed, AID is
required for MYC-IGH chromosomal translocations in
vivo.96 Moreover, loss of AID in Eµ-MYC mice changed the
lymphoma phenotype from B- cell to pre-B cell tumors, fur-
ther suggesting that AID activity contributes to mature B-
cell but not to pre-B cell lymphoma development.97 Why
the selective deregulation of MYC in germinal center B
cells in the Vk*MYC mice failed (again) to reproduce the
human disease phenotype is not fully understood.
However, this model reinforces the concept that the single
deregulation of MYC in centroblasts is sufficient to direct-
ly induce malignant transformation. 
Epigenetic modifications in B-cell lymphomagenesis 
It is widely accepted that cancers are heterogeneous dis-
orders caused by a series of clonally selected genetic and
epigenetic changes in tumor genes. However, some cancers
may originate from a polyclonal epigenetic alteration of
stem or progenitor cells within specific tissues, initially
producing a pre-neoplastic epigenetically aberrant state.98
Recent studies have provided additional evidence for an
instructive mechanism behind aberrant DNA methylation
in cancer, which might indicate that specific DNA
sequences are predisposed to acquire epigenetic aberra-
tions.99,100 Indeed, a highly significant proportion of genes
that are hypermethylated in solid tumors were already
repressed at the embryonic stem cell stage by PcG marks.100
These findings support the cancer stem cell theory by stating
that aberrant epigenetic changes of PcG-target genes might
represent an initial event in tumorigenesis.101 Moreover, the
genome-wide methylation pattern observed in a mouse
model of MYC-induced lymphomas was driven by the
genetic configuration of tumor cells, providing experimen-
tal evidence for a causal role of DNA hypermethylation in
tumor progression.102
Martin-Subero et al. have recently studied the DNA
methylation profiles of different morphological, genetic
and transcriptional subtypes of lymphomas, including
Burkitt’s lymphoma, activated B-cell DLBCL, and germinal
center-like DLBCL.103 Hierarchical clustering of microarray-
based DNA methylation data indicated that DNA methy-
lation patterns in lymphoma cells were not strictly associ-
ated with morphological, genetic or transcriptional fea-
tures. Using supervised analyses, however, they identified
a small group of genes that appeared to be de novo methy-
lated in a lymphoma subtype-specific manner. Strikingly, a
different set of genes was methylated in all lymphoma sub-
types and unmethylated in hematopoietic controls. This
latter group of genes was mostly unmethylated in adult
and embryonic stem cells and highly enriched for PcG tar-
gets in embryonic stem cells. 
These findings could on one hand suggest that mature
aggressive B-cell lymphomas with different genetic back-
grounds might derive from lymphoma precursor cells with
similar stem cell-like features that have acquired aberrant
methylation of PcG target genes.103 Alternatively, an epige-
netic footprint of stemness could have been acquired during
lymphomagenesis by epigenetic remodeling.
Consequently, as an alternative hypothesis to the develop-
ment of lymphoma by linear acquisition of chromosomal
translocations in lymphoid precursor or progenitor cells
followed by reprogramming mutations, we may postulate
that epigenetically aberrant lymphoma-initiating stem or
progenitor cells that retain stem-cell features are suscepti-
ble to malignant transformation when acquiring, for
instance, BCL2 or BCL6 gene rearrangements, during their
transit through the bone marrow or the germinal center.
Lymphoma-originating cells: a therapeutic
perspective
Most conventional chemotherapy kills rapidly proliferat-
ing tumor cells whereas cancer stem cells may remain
viable during treatment because of their relative quies-
cence. At the end of treatment, cancer stem cells may
regenerate the tumor entirely, providing one possible
explanation of why tumors can relapse in patients in
apparent complete clinical remission.1,9,104 Consequently,
destruction of the stem cell population capable of initiating
and maintaining tumors has become a major goal in the
treatment of human malignancies. FL is characterized by
the t(14;18)(q32;q21) resulting in overexpression of BCL2
protein. Most patients with FL initially respond to
chemotherapy, but they typically experience relapses
and/or transformation into high-grade therapy-resistant
lymphoma.105 Thus, it is still considered an incurable dis-
ease using conventional treatment approaches. In mice,
forced expression of the anti-apoptotic BCL2 protein in
HSCs makes them more resistant to radiotherapy.106 In
human biopsies, Dogan et al. identified an interfollicular
neoplastic B-cell population surrounding the malignant fol-
licles in the majority of FLs. While both follicular and inter-
follicular cell populations shared clonal identity, the latter
showed low-grade cytological features, lower proliferation
activity and downregulation of activation markers such as
CD19, CD38 and CD95, suggesting that these more quies-
cent cells may partially account for FL therapeutic resist-
ance.107 Based on these reports , we may postulate that the
yet unidentified FL-originating cells express high levels of
BCL2 and are slowly proliferating, making them resistant
to standard chemo/radiotherapy, whereas most other FL
cells are killed following treatment. At the conclusion of a
treatment regimen, the quiescent cell population regener-
ates the lymphoma, requiring further treatments followed
by subsequent relapses that are accompanied by novel sto-
chastic genetic changes that ultimately lead to transforma-
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tion to DLBCL in those patients destined to transform.
Therefore, identification of the FL-originating cells seems
crucial to better define future treatment strategies. For
instance, one promising therapy in FL is ABT-737, a small-
molecule inhibitor of BCL2, which is effective in solid
tumors.108 However, whether this and other similar anti-
BCL2 compounds will be active against the FL-originating
cells or will otherwise encounter selective resistance (mim-
icking imatinib therapy in CML) remains unclear. Another
issue is whether the FL negative for BCL2 expression will
respond to these compounds.109 A different example is the
monoclonal antibody against CD20 (rituximab), which has
shown clinical benefit for both induction and maintenance
therapy in FL clinical trials.105 Whether rituximab given in
combination with chemotherapy will eventually achieve
cure in FL or will simply prolong complete remissions is
uncertain, but may in part depend on whether the FL-orig-
inating cells express CD20 on the cell surface in a configu-
ration and antigen density that allows this targeted thera-
py to kill them. 
Stem cells reside in a special microenvironment termed
the niche, where they interact via adhesion molecules and
exchange molecular signals that maintain the specific fea-
tures of stem cells. Based on these findings, it has been
shown that a cancer stem cell niche exists, being involved in
cancer stem cell regulation, tumor invasion, and metasta-
sis.110 Although there has not been a formal demonstration
of the existence of a niche for the putative lymphoma-orig-
inating cells, these niches may serve as reservoirs that pro-
tect these cells from current therapies.
Conclusions
B-cell non-Hodgkin’s lymphomas, in contrast to most
leukemias, are derived from either committed lymphoid
progenitor/precursor cells or from more mature B-lympho-
cytes that acquire chromosomal translocations through
errors in the IG gene remodeling processes during normal
B-cell differentiation. These lymphoma-initiating cells har-
boring characteristic chromosomal translocations are pre-
malignant cells unable to form tumors, needing to acquire
stem-cell features through secondary reprogramming
mutations to become the lymphoma-originating cells fully
capable of generating and maintaining lymphomas. While
this scenario applies to FL and MCL, diffuse large B-cell
lymphoma and Burkitt’s lymphoma are derived from more
mature germinal center-derived lymphocytes. Although
reprogramming mutations are also required in most cases,
centroblasts or memory B cells that have certain stem cell-
like properties and are targeted by translocations or lym-
phocytes that suffer MYC rearrangements that deregulate
self-renewal pathways may not need these secondary
mutations, directly functioning as lymphoma-originating
cells able to drive malignancy. An alternative hypothesis
states that the first hit consists of an aberrant epigenetic
state of stem or progenitor cells that either retain stem cell-
like features or reprogram stemness into more mature cells,
followed by chromosomal instability and subsequent
genetic aberrations that eventually lead to lymphoma for-
mation. Detailed isolation and molecular characterization
of the specific cells of origin for each B-cell lymphoma enti-
ty are crucial steps not only to better understand lym-
phomagenesis but also to make meaningful improvements
in the treatment and eventual cure of these patients. 
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